Results 91 to 100 of about 8,627 (176)

Possibilities for monitoring the pharmacodynamics of dabigatran etexilate

Якутский медицинский журнал
The sensitivity and prognostic value of laboratory tests and methods for assessing pharmacodynamics in relation to the system of regulation of the aggregate state of blood after a single dose of dabigatran etexilate at a dosage of 150 mg were ...
M. A. Solovyev, D. A. Momot, L. Y. Kotlovskaya, I. I. Tyutrin, V. V. Udut   +4 more
doaj   +1 more source

Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate. [PDF]

CPT Pharmacometrics Syst Pharmacol, 2021
Farhan N, Cristofoletti R, Basu S, Kim S, Lingineni K, Jiang S, Brown JD, Fang LL, Lesko LJ, Schmidt S.   +9 more
europepmc   +1 more source

Adverse events in patients initiated on dabigatran etexilate therapy in a pharmacist-managed anticoagulation clinic

, 2013
Background: Vitamin K antagonists have been the treatment of choice in preventing thromboembolic events, but problems such as frequent dose adjustment and monitoring of coagulation status, including multiple drug and food interactions, make their use ...
Norbeck AO, Donaldson M
core   +2 more sources

Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. [PDF]

J Thromb Haemost, 2021
Röshammar D, Huang F, Albisetti M, Bomgaars L, Chalmers E, Luciani M, Halton J, Mitchell LG, Bergstrand M, Ibrahim MMA, Joseph D, Tartakovsky I, Gropper S, Brueckmann M, Brandão LR.   +14 more
europepmc   +1 more source

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective

, 2011
SummaryOral dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in whom anticoagulation is appropriate.
Anuraag Kansal, Sonja Sorensen, Carole Bradley-Kennedy, Jonathan Plumb, John Linnehan, Stuart Connolly, Siyang Peng   +6 more
core   +1 more source

Comparison of the efficacy of rivaroxaban and dabigatran etexilate in preventing venous thrombosis after arthroplasty: A protocol of randomized controlled trial. [PDF]

Medicine (Baltimore), 2021
Song R, Qu R, Wang Y, Zhou D, Zhang A.
europepmc   +1 more source

Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate. [PDF]

J Thromb Haemost, 2021
van Gorp RH, Dijkgraaf I, Bröker V, Bauwens M, Leenders P, Jennen D, Dweck MR, Bucerius J, Briedé JJ, van Ryn J, Brandenburg V, Mottaghy F, Spronk HMH, Reutelingsperger CP, Schurgers LJ.   +14 more
europepmc   +1 more source

Expanding horizons of anticoagulant therapy: Dabigatran etexilate a novel oral anticoagulant [PDF]

, 2017
Thrombo-embolic disease is a major challenging clinical problem associated with significant mortality and morbidity. Anticoagulation with the existing heparin products and vitamin K antagonist (VKA) anticoagulants are still the mainstay of management ...
Vieira, Alfven, Ghanekar, Jaishree, Jadhav, Pradeep, Ray, Ipseeta, Deshmukh, Yeshwant A.   +4 more
core  

New options with dabigatran etexilate in anticoagulant therapy

Vascular Health and Risk Management, 2010
Lars Maegdefessel, Joshua M Spin, Junya Azuma, Philip S TsaoDepartment of Cardiovascular Medicine, Stanford University – School of Medicine, Stanford, CA, USAAbstract: Thrombosis, the localized clotting of blood, occurs in both the arterial and
Lars Maegdefessel, Joshua M Spin, Junya Azuma, et al   +3 more
doaj  

Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. [PDF]

Eur J Drug Metab Pharmacokinet, 2020
Duan J, Duan J, Yang L, Li H, Yamamura N, Harada A.   +5 more
europepmc   +1 more source